Clinical Study Results, Stock Price Movements, and Acquisitions - Research Report on Gilead, Life Technologies, Jazz Pharmaceuticals, CSI, and Smith & Nephew Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, December 11, 2013 NEW YORK, December 11, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Life Technologies Corp. (NASDAQ: LIFE), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Cardiovascular Systems Inc. (NASDAQ: CSII), and Smith & Nephew plc (ADR) (NYSE: SNN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Gilead Sciences, Inc. Research Report On December 8, 2013, Gilead Sciences, Inc. (Gilead) announced the results of a Phase 2 study (Study 101-09) evaluating idelalisib (an investigational oral inhibitor of PI3K delta) for the treatment of patients with indolent non-Hodgkin's lymphoma (iNHL), which is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. Gilead informed that in the study, single-agent treatment with idelalisib achieved an overall response rate of 57% with a median duration of response of 12.5 months. Gilead further informed that of the 71 patients who responded to therapy, seven (6%) achieved a complete response, 63 (50%) had a partial response and one (1%) had a minor response. Ajay Gopal, M.D., Associate Professor, University of Washington School of Medicine and Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, said, "It has been more than ten years since a treatment with a novel mechanism of action has been approved for indolent NHL, underscoring the medical need for new treatments for patients who are no longer responsive to currently available therapies." Dr. Gopal added, "The overall response rate and durability of response observed in this study suggest that idelalisib may become a valuable new therapy for iNHL patients who have very limited treatment options." The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/9898_GILD -- Life Technologies Corp. Research Report On December 6, 2013, Life Technologies Corp.'s (Life Technologies) stock rose 0.09%, ending the day at $75.69. Over the previous three trading sessions, shares of Life Technologies gained 0.12% compared to the Nasdaq Composite which gained 0.63% during the same period. The Full Research Report on Life Technologies Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/d5de_LIFE -- Jazz Pharmaceuticals plc Research Report On December 6, 2013, Jazz Pharmaceuticals plc's (Jazz Pharmaceuticals) stock rose 2.36%, ending the day at $117.04. Over the previous three trading sessions, shares of Jazz Pharmaceuticals gained 2.84% compared to the Nasdaq Composite which gained 0.63% during the same period. The Full Research Report on Jazz Pharmaceuticals plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/5fe3_JAZZ -- Cardiovascular Systems Inc. Research Report On December 3, 2013, Cardiovascular Systems Inc. (CSI) announced that the Company's Diamondback 360 Coronary Orbital Atherectomy System (OAS) is being used by physicians across the country to treat coronary artery disease. CSI reported that this has followed the Company's recent PMA (premarket approval application) approval from the US Food and Drug Administration (FDA) to market the device as a treatment for severely calcified coronary arteries. David L. Martin, CSI's President and CEO, said, "Significant arterial calcium is present in nearly 40 percent of patients undergoing a percutaneous coronary intervention, and contributes to poor outcomes and higher treatment costs in coronary interventions when traditional therapies are used-including a substantially higher occurrence of death and major adverse cardiac events." Martin added, "Severe coronary arterial calcium is a vastly underestimated problem in medicine, with limited treatment options. Our Diamondback 360 coronary system provides for initial therapeutic intervention for this complex disease and we are excited about its growing use, as illustrated by the early adoption and ongoing cases being performed at three U.S. hospitals by prominent physicians. As we continue our controlled product rollout, we expect to see this list of hospitals and prominent physicians expand nationally." The Full Research Report on Cardiovascular Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/11b9_CSII -- Smith & Nephew plc (ADR) Research Report On November 26, 2013, Smith & Nephew plc (ADR) (Smith & Nephew) announced that it has agreed to acquire the assets and business of Politec Saúde relating to Smith & Nephew's Advanced Wound Management products in Brazil. According to the Company, the proposed acquisition promises approximately one quarter of Politec's overall business. Smith & Nephew, however, did not disclose the terms of the transaction. Olivier Bohuon, CEO of Smith & Nephew, added, "Being closer to the customer is at the heart of our Emerging Markets strategy. Brazil is an exciting long-term opportunity and this is an important investment which creates a significant platform from which we can grow." The Full Research Report on Smith & Nephew plc (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/eed3_SNN ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Clinical Study Results, Stock Price Movements, and Acquisitions - Research Report on Gilead, Life Technologies, Jazz
Press spacebar to pause and continue. Press esc to stop.